The long‐acting β2‐agonist salmeterol xinafoate: effects on airway inflammation in asthma
نویسندگان
چکیده
منابع مشابه
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma.
Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently introduced for the treatment of asthma. Both in vitro and animal studies suggest that it may have anti-inflammatory activities of benefit in this disease. To assess this directly, the effects of 6 weeks' treatment with salmeterol on indices of clinical activity, airway dysfunction and inflammation in subjects wit...
متن کاملThe effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma.
STUDY OBJECTIVE To determine the efficacy of salmeterol alone in a group of patients with moderate asthma with nocturnal worsening of symptoms. DESIGN Double-blind, randomized, placebo-controlled crossover study. SETTING Tertiary care hospital specializing in respiratory diseases. PARTICIPANTS Ten patients with nocturnal asthma. INTERVENTIONS Subjects were randomized to salmeterol, 100 ...
متن کاملEffect of salmeterol on allergen-induced airway inflammation in mild allergic asthma.
A previous study suggested that the long-acting beta2-adrenergic agonist salmeterol (SM) had inhibitory effects on bronchial mucosal inflammation 6 hours after allergen exposure. To further evaluate the influence of SM on allergen-induced airway inflammation. We studied, in a randomized, double-blind, cross-over trial, 16 mild asthmatic patients who had a dual asthmatic response to allergen inh...
متن کاملEffect of Salmeterol on Allergen- Induced Airway Inflammation in Mild Allergic Asthma
then done with either placebo (n 21) or salmeterol 42 g twice daily (n 154) for 2 weeks at stable doses. Next was an ICS reduction phase over the next 8 weeks as all 21 patients on triamcinolone plus placebo were assigned to receive half the dose of triamcinolone 200 g twice daily plus continued placebo (placebo–minus group). Patients on full dose ICS plus salmeterol were randomized to either c...
متن کاملEfficacy of salmeterol xinafoate in the treatment of COPD.
STUDY OBJECTIVES To examine and compare the efficacy and safety of salmeterol xinafoate, a long-acting inhaled beta2-adrenergic agonist, with inhaled ipratropium bromide and inhaled placebo in patients with COPD. DESIGN A stratified, randomized, double-blind, double-dummy, placebo-controlled, parallel group clinical trial. SETTING Multiple sites at clinics and university medical centers thr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 1999
ISSN: 0903-1936,1399-3003
DOI: 10.1034/j.1399-3003.1999.14b07.x